Cefonicid

Cefonicid

SCHEMBL41894

O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12.[NaH]

nearest known ligand 0.99

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Cefonicid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.99
SLC22A6 Q4U2R8 2/20 0.76
SLC22A8 Q8TCC7 2/20 0.76
SLC22A11 Q9NSA0 2/20 0.76
NR1I2 O75469 1/20 0.76
PGR P06401 1/20 0.76
PPARG P37231 1/20 0.76
TDP1 Q9NUW8 10/20 0.67
MAPT P10636 9/20 0.67
POLB P06746 9/20 0.67
HSD17B10 Q99714 6/20 0.67
ALDH1A1 P00352 5/20 0.67
KDM4E B2RXH2 2/20 0.67
CYP3A4 P08684 1/20 0.67
HPGD P15428 1/20 0.67
APEX1 P27695 1/20 0.67
PTPN7 P35236 1/20 0.67
LMNA P02545 2/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cefonicid SCHEMBL27856008 1.00 SLC6A4 (0.99) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2
Cefonicid SCHEMBL8425120 1.00 SLC6A4 (0.99) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2
Cefonicid SCHEMBL16072827 0.99 SLC6A4 (1.00) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2
Cefonicid SCHEMBL18048103 0.99 SLC6A4 (1.00) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2
Cefonicid SCHEMBL60350 0.99 SLC6A4 (1.00) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2
Cefonicid SCHEMBL13297839 0.99 SLC6A4 (1.00) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2
Cefonicid SCHEMBL9080022 0.99 SLC6A4 (1.00) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2
Cefonicid SCHEMBL537693 0.99 SLC6A4 (1.00) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2
Cefonicid SCHEMBL28744041 0.99 SLC6A4 (0.99) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2
Cefonicid SCHEMBL27865839 0.99 SLC6A4 (0.99) SLC6A4SLC22A6SLC22A8SLC22A11NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2615 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
CN-112912386-B Cell penetrating peptides based on influenza virus M2 proteins 中国医学科学院基础医学研究所 2023-10-20 CN claimed
CN-111072497-B Method for recovering N, N' -dibenzylethylenediamine salt from ion exchange resin to be regenerated of cefonicid sodium 华北制药河北华民药业有限责任公司 2022-10-25 CN claimed
US-20220169680-A1 CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-06-02 US claimed
EP-3912989-A1 CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) 2021-11-24 EP claimed
CN-113559264-A Methods of treating microbial infections including mastitis 罗达制药公司 2021-10-29 CN claimed
CN-113144197-A Method of treating topical microbial infections 罗达制药公司 2021-07-23 CN claimed
CN-112912386-A Cell penetrating peptide based on influenza virus M2 protein 中国医学科学院基础医学研究所 2021-06-04 CN claimed
US-20030064097-A1 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents LIPOCINE INC. 2003-04-03 US claimed
EP-1233756-A1 SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS Lipocine, Inc. (US) 2002-08-28 EP claimed
US-20020107265-A1 EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS LIPOCINE INC. 2002-08-08 US claimed
EP-1210063-A1 COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS Lipocine, Inc. (US) 2002-06-05 EP claimed
US-6309663-B1 Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents LIPOCINE INC. 2001-10-30 US claimed
US-6248363-B1 Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents LIPOCINE, INC. 2001-06-19 US claimed
US-6245735-B1 CONJUGATE OF ANTIBIOTIC AND POLYPEPTIDE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR OR LIPOPOLYSACCHARIDE BINDING FRAGMENT THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2001-06-12 US claimed
WO-2001037808-A1 SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS LIPOCINE, INC. (US) 2001-05-31 WO claimed
WO-2001028555-A1 EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS LIPOCINE, INC. (US) 2001-04-26 WO claimed
WO-2001012155-A1 COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS LIPOCINE, INC. (US) 2001-02-22 WO claimed